View in EDS

Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies.

Saved in:
Bibliographic Details
Title: Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies.
Authors: Miller MJ; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, CA 91320, United States of America. Electronic address: millermj@amgen.com., Kroenke MA; Clinical Immunology, Amgen, Thousand Oaks, CA 91320, United States of America., Barger T; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, CA 91320, United States of America., Manning MS; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, CA 91320, United States of America., Sohn W; Clinical Pharmacology Modeling and Simulation, Amgen, Thousand Oaks, CA 91320, United States of America., Graham K; Large Molecule Discovery & Research Data Science, Amgen, Thousand Oaks, CA 91320, United States of America., Mytych DT; Clinical Immunology, Amgen, Thousand Oaks, CA 91320, United States of America., Gupta S; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, CA 91320, United States of America.
Source: Journal of immunological methods [J Immunol Methods] 2025 May; Vol. 540, pp. 113864. Date of Electronic Publication: 2025 Apr 10.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1305440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7905 (Electronic) Linking ISSN: 00221759 NLM ISO Abbreviation: J Immunol Methods Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-7905
DOI:10.1016/j.jim.2025.113864